Results 111 to 120 of about 961 (135)

Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk

Biological Psychiatry, 2001
This study's goal was to characterize nursing infants' exposure to fluoxetine through breast milk and to identify variables for minimizing such exposure.Nursing women on stable daily doses of fluoxetine were recruited into the study. Breast milk, maternal and infant serum concentrations of fluoxetine and norfluoxetine were determined with high ...
V, Hendrick, Z N, Stowe, L L, Altshuler, J, Mintz, S, Hwang, A, Hostetter, R, Suri, K, Leight, A, Fukuchi   +8 more
openaire   +2 more sources

Determination of Fluoxetine and Norfluoxetine Concentrations in Cadaveric Allograft Skin

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1998
Fluoxetine hydrochloride is the sixth most prescribed drug in the United States and is administered to treat major depression. A cadaveric skin donation was obtained from a 46‐year‐old woman who died as a result of a fluoxetine overdose. Due to the potential penetration of the drug and its major metabolite, norfluoxetine, into skin, the safety of using
Neudeck, Brien L., Taddonio, Thomas E., Garner, Warren L., Welage, Lynda S.   +3 more
openaire   +3 more sources

STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP

Drug Metabolism and Disposition, 2004
We examined the stereoselective disposition of fluoxetine (FX) and its metabolite norfluoxetine (NFX) in five pregnant sheep. Racemic FX was administered i.v. to the ewe (50 mg) and the fetus (10 mg) on separate occasions. Maternal and fetal blood, maternal urine, and fetal amniotic and tracheal fluid samples were collected for 72 h. FX and NFX isomers
John, Kim, K Wayne, Riggs, Dan W, Rurak
openaire   +2 more sources

Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine

Naunyn-Schmiedeberg's Archives of Pharmacology, 1996
Fluoxetine and its primary metabolite, norfluoxetine, are inhibitors of neuronal uptake of 5-hydroxytryptamine. While fluoxetine has also been reported to inhibit monoamine oxidase (MAO) in vitro at concentrations much lower than those measured in brain following chronic fluoxetine treatment, neurochemical profiles are not consistent with substantial ...
A, Holt, G B, Baker
openaire   +2 more sources

Enantioselective quantification of fluoxetine and norfluoxetine by HPLC in wastewater effluents

Chemosphere, 2014
Microbial degradation is the most important process to remove organic pollutants in Waste Water Treatment Plants. Regarding chiral compounds this process is normally enantioselective and needs the suitable analytical methodology to follow the removal of both enantiomers in an accurate way. Thus, this paper describes the development and validation of an
Ribeiro, Ana R., Maia, Alexandra S., Moreira, Irina S., Afonso, Carlos M., Castro, Paula M.L., Tiritan, Maria E.   +5 more
openaire   +3 more sources

Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling

The Journal of Clinical Pharmacology, 2021
AbstractFluoxetine is a selective serotonin reuptake inhibitor that is metabolized to norfluoxetine by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. A physiologically based pharmacokinetic model for fluoxetine and norfluoxetine metabolism was developed to predict and investigate changes in concentration‐time profiles according to fluoxetine dosage in
Hyeon-Cheol, Jeong, Yoon-Jee, Chae, Sooyeun, Lee, Wonku, Kang, Hwi-Yeol, Yun, Kwang-Hee, Shin   +5 more
openaire   +2 more sources

Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies

Brain Research Bulletin, 2005
Norfluoxetine is the most important active metabolite of the widely used antidepressant fluoxetine but little is known about its pharmacological actions. In this study the anticonvulsant actions of norfluoxetine and fluoxetine were studied and compared to those of phenytoin and clonazepam in pentylenetetrazol-induced mouse epilepsy models. Pretreatment
Valéria, Kecskeméti, Zoltán, Rusznák, Pál, Riba, Balázs, Pál, Róbert, Wagner, Csaba, Harasztosi, Péter P, Nánási, Géza, Szûcs   +7 more
openaire   +2 more sources

Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration

American Journal of Psychiatry, 1992
In vivo 19fluorine nuclear magnetic resonance spectroscopy was used to measure the brain concentration of fluoxetine and norfluoxetine in five patients with obsessive-compulsive disorder and three with major depression. The mean brain:plasma ratio of the parent drug plus the metabolite was significantly elevated to 2.6 (SD = 1.0) (95% confidence ...
P F, Renshaw, A R, Guimaraes, M, Fava, J F, Rosenbaum, J D, Pearlman, J G, Flood, P R, Puopolo, K, Clancy, R G, Gonzalez   +8 more
openaire   +2 more sources

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study

American Journal of Psychiatry, 1997
Prior studies examining the relationship between fluoxetine plasma concentrations and response in major depression have either found no relationship between plasma concentration and response or suggested a curvilinear relationship with a therapeutic window.
J D, Amsterdam, J, Fawcett, F M, Quitkin, F W, Reimherr, J F, Rosenbaum, D, Michelson, M, Hornig-Rohan, C M, Beasley   +7 more
openaire   +2 more sources

Excretion of Fluoxetine and Its Metabolite, Norfluoxetine, in Human Breast Milk

The Journal of Clinical Pharmacology, 1996
A study was conducted to measure breast milk concentrations of fluoxetine and its active metabolite, norfluoxetine, excreted in breast milk in a cohort of nursing women using fluoxetine, and to estimate infant dose from nursing. The study included 10 women nursing 11 infants (median age, 185 days). The mean fluoxetine dose was 0.39 mg/kg/day.
A, Taddio, S, Ito, G, Koren
openaire   +2 more sources